Navigation Links
New stroke treatments becoming a reality
Date:7/26/2012

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

Professor Dame Nancy Rothwell, Professor Stuart Allan and their team have spent the last 20 years investigating how to reduce damage to the brain following a stroke.

They have been testing the effectiveness of the drug Anakinra (IL-1Ra), which is already used for rheumatoid arthritis in experimental studies of stroke.

This new study builds on previous research, although the big difference is that rats with stroke risk factors such as obesity, insulin resistance and atherosclerosis were used alongside healthy rats and older ones. It means the findings have a far greater chance of being replicated in human stroke patients.

Researchers induced a stroke in the rats and the drug IL-1Ra, or a placebo for comparison, was injected under the skin. The researchers did not know which animals had been given which drug. This is a similar process to what happens in clinical trials of medicines.

The results were startling. MRI scans revealed that the rats that were given IL-1Ra up to three hours after the stroke had only about half the brain damage of the placebo group.

Professor Rothwell said: "This is the first time that we are aware of a potential new treatment for stroke being tested in animals with the same sort of diseases and risk factors that most patients have. The results are very promising and we hope to undertake further clinical studies in stroke patients soon."

IL-1Ra works by blocking the naturally occurring protein interleukin 1. Researchers at The University of Manchester have identified that it is a key cause of brain injury following a stroke.

Interleukin 1 encourages inflammation in the area of the brain affected by stroke. This sends out signals to attract white blood cells and to switch on microglia cells in the brain. Because the barrier surrounding the brain has been weakened by the stroke the white blood cells find it easier to enter the brain. But instead of helping the inflamed area they actually kill nerve cells and worsen the injury. The increasing presence of these cells also explains why the damage in the brain gets worse over time following a stroke.

IL-1Ra also reduces the amount of damage to the blood-brain barrier following a stroke so the harmful cells can't enter the brain. In the recent experiments IL-1Ra reduced the damage to the blood-brain barrier by 55% in healthy rats and 45% in rats with underlying health conditions. In all types of rats the drug reduced the amount of activated microglia cells by 40% compared to the placebo group.

The only drug treatment currently available for stroke patients is Tissue Plasminogen Activator (tPA). However, this can only be administered to patients who suffer from a blood clot (ischaemic stroke) rather than bleeding. A brain scan is required to assess which type of stroke a patient has suffered which is why it is essential to get them to hospital as quickly as possible. tPA also has to be administered within a few hours of a stroke to be effective.

Professor Stuart Allan at The University of Manchester hopes that IL-1Ra could be used for both forms of stroke, meaning it could be administered immediately.

He said: "This drug has real potential to save lives and stop hundreds of thousands of people being seriously disabled by stroke. This really could be the treatment for stroke that we've been looking for over the past two decades."

A phase 2 trial with a small number of patients has yielded encouraging results. It's hoped a much larger clinical trial will demonstrate the effectiveness of IL-1Ra in reducing brain damage in stroke patients and that eventually it will become the standard treatment.


'/>"/>
Contact: Morwenna Grills
Morwenna.Grills@manchester.ac.uk
44-161-275-2111
University of Manchester
Source:Eurekalert

Related medicine news :

1. Predictors identified for rehospitalization among post-acute stroke patients
2. Could Menthol Cigarettes Pose Even Higher Stroke Risk?
3. NJ stroke researchers report advances in spatial neglect research at AAN Conference
4. Mobile Stroke Units Might Trim Time to Treatment
5. Spouses of Cancer Patients May Have Raised Risk of Heart Disease, Stroke
6. Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat
7. Cedars-Sinai stroke team earns award for improving regions quality of care
8. Procedure gives patients with A-fib who cant take blood thinners alternative to reduce stroke
9. Irregular Heartbeat Poses Greater Stroke Risk for Women Than Men
10. Elderly women with irregular heart beat at higher risk for stroke
11. Rate of Hospitalizations for Stroke Has Declined in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
Breaking Medicine Technology: